New pill for rheumatoid arthritis enters first human tests

NCT ID NCT07266207

Completed Disease control Sponsor: Artivila (Shenzhen) Innovation Center, Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested ARD-885, a new oral drug that targets two proteins involved in inflammation, in 94 healthy volunteers and people with rheumatoid arthritis. The main goal was to check safety and how the body processes the drug. Researchers gave single and multiple doses, and also looked at the effect of food. This is a first step to see if the drug is safe enough for larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ARD-885 tablets (a drug that targets inflammation pathways)
What this could lead to: If successful, this could lead to a new oral treatment option for rheumatoid arthritis that helps control joint inflammation and pain.
What could go wrong: This is a very early Phase 1 trial focused on safety and dosing, not on effectiveness. The drug may not work or could have side effects. Results in healthy people may not apply to RA patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS (RA)

Contacts and locations

Locations

The Second Affiliated Hospital of Anhui Medical University

Hefei, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.